Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsSystematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus IsolatesCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciRelationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infectionsTreatment of Gram-positive infections in critically ill patientsSynergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelAntibacterial Evaluation of Synthetic Thiazole Compounds In Vitro and In Vivo in a Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infection Mouse ModelDetection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. auClinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care unitsHigh-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Predicting risk for death from MRSA bacteremia.Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agentPrevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at a major New York HospitalPrevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significanceIs it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic wavesClinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream InfectionPrevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus.Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolatesCurrent and prospective treatments for multidrug-resistant gram-positive infections.Methicillin-resistant Staphylococcus aureus: an evolving pathogen.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus.Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.
P2860
Q24646677-0BEDA7E4-DC46-495D-8675-CF2511E66E9DQ26796560-D20F689A-2C95-4738-BFBF-BDAA039D3648Q26853465-C4C8B38C-3726-4DF4-ABEE-0BFE3441F4F3Q27011138-DDD0BC03-253B-45B2-8E3C-F2E3D06AFDA6Q27015976-1C2C110A-227C-44CD-99FF-DD5A9C888742Q28481497-A9697541-6DFE-49E9-9B07-9F0B70C2A138Q28550691-7D2DCD56-A618-4CD2-A0EE-D49EA9FF4264Q33613735-0416330E-92B7-4662-9D2A-6D4E4C2CFA2FQ33826253-60C1A98A-5B1A-4680-A62F-888355C1F9ABQ33945397-C1EDA57E-C3C0-4A8C-92B3-1EAAD4A7F98FQ34290139-9CEB2DAF-0DA2-45BC-B758-78CB28DA28BFQ34998629-7A7AF6BA-4E5B-4375-BF98-6AB5FBD4BB38Q35064413-99E8B981-8FF2-42A3-B4E5-8331CD26F480Q35066896-C0DA7FF3-F26A-40B0-AEFF-EB249D9F5198Q35819831-92E5E8EE-482D-4278-A430-91FF2C61C8E4Q35848781-85873DF2-7477-4D50-98B4-FFBAB0FFE239Q35959546-BA768C79-E653-4FE6-A65A-8D596B212C15Q36037687-49F47BC6-6B82-4A79-953C-01F0E6EABFBDQ36265781-5F0D707E-5F7F-4D02-977A-5CEA8F11CF12Q36501398-600E917C-B30E-417F-9A26-C5C1B52BE8A4Q36636699-EA8C680E-5290-4D41-881E-8B8D223F4DE9Q36644689-CB7A083D-2278-48FE-A97E-3E9EF4673424Q36692468-6C0F1E65-BE20-4936-A05D-A12D01D9399BQ36856946-C2179F15-9DF7-46B6-A6B8-CB2EAED322DCQ36999966-C4DFDB32-962F-4520-B581-48419240312EQ37124131-9D821C4F-7EF0-4E6F-B663-09D83B790C9FQ37333104-5DA3320B-4A08-418A-802B-76C8FE38B897Q37581376-1CD7EDFA-DA81-4857-8063-30701CD97F24Q37717901-52D0A21F-31DF-448E-BD69-7D00363DBBF8Q37809666-1A3DDA74-0E8A-4F7D-96BB-C740992C1757Q38123255-6DD7C9D7-D323-494B-A54F-C2C07233B422Q38171759-9C98246F-5E91-4D93-BEBA-98DC2CF47D00Q38425879-4831E76E-050F-46CC-980B-E65CD793E3B3Q38462842-2069A935-D45E-4797-8DD1-557730348181Q38615330-8DB17B1F-96C6-47E3-AF10-2CD3A02CD4F8Q40003834-5C46EDD6-89FB-400C-848F-EC17C582F526Q40098505-5C501FC7-4AFE-42C3-84E3-574E0A223809Q40261278-4262AB51-81D8-41CD-9B30-AE7E3F604FCDQ40600332-5B5820F8-55B8-4CB9-A003-2E317B9F2D53Q41016957-45E5E730-5A26-4E42-BE90-4BE9B1879066
P2860
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Characterization of vancomycin ...... 22-year period (1986 to 2007).
@en
type
label
Characterization of vancomycin ...... 22-year period (1986 to 2007).
@en
prefLabel
Characterization of vancomycin ...... 22-year period (1986 to 2007).
@en
P2093
P2860
P356
P1476
Characterization of vancomycin ...... 22-year period (1986 to 2007).
@en
P2093
Chrissy M Cheung
Kerri L Rossi
Michael J Rybak
Ronald N Jones
Steve N Leonard
P2860
P304
P356
10.1128/JCM.00582-08
P407
P577
2008-07-16T00:00:00Z